Pharmacogenetic Information in Clinical Guidelines: The European Perspective

on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)

doi:10.1002/cpt.1049

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Review article › peer-review

Abstract

Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx). ^1-3 In addition, patients are willing to consent to participate in PGx implementation studies. ⁴ However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test. ^1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients. ^5,6 .

Original language	English
Pages (from-to)	795-801
Number of pages	7
Journal	Clinical Pharmacology and Therapeutics
Volume	103
Issue number	5
DOIs	https://doi.org/10.1002/cpt.1049
Publication status	Published - 1 May 2018

Access to Document

10.1002/cpt.1049

Cite this

@article{0bb38b4a2be647c6bab0478e94432059,

title = "Pharmacogenetic Information in Clinical Guidelines: The European Perspective",

abstract = " Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx). 1-3 In addition, patients are willing to consent to participate in PGx implementation studies. 4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test. 1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients. 5,6 . ",

author = "\{on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)\} and Swen, \{Jesse J.\} and Marga Nijenhuis and \{van Rhenen\}, Mandy and \{de Boer-Veger\}, \{Nienke J.\} and Buunk, \{Anne Marie\} and Houwink, \{Elisa J.F.\} and Hans Mulder and Rongen, \{Gerard A.\} and \{van Schaik\}, \{Ron H.N.\} and \{van der Weide\}, Jan and Bob Wilffert and Deneer, \{Vera H.M.\} and Guchelaar, \{Henk Jan\}",

year = "2018",

month = may,

day = "1",

doi = "10.1002/cpt.1049",

language = "English",

volume = "103",

pages = "795--801",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Pharmacogenetic Information in Clinical Guidelines

T2 - The European Perspective

AU - on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)

AU - Swen, Jesse J.

AU - Nijenhuis, Marga

AU - van Rhenen, Mandy

AU - de Boer-Veger, Nienke J.

AU - Buunk, Anne Marie

AU - Houwink, Elisa J.F.

AU - Mulder, Hans

AU - Rongen, Gerard A.

AU - van Schaik, Ron H.N.

AU - van der Weide, Jan

AU - Wilffert, Bob

AU - Deneer, Vera H.M.

AU - Guchelaar, Henk Jan

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx). 1-3 In addition, patients are willing to consent to participate in PGx implementation studies. 4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test. 1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients. 5,6 .

AB - Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx). 1-3 In addition, patients are willing to consent to participate in PGx implementation studies. 4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test. 1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients. 5,6 .

UR - https://www.scopus.com/pages/publications/85044533453

U2 - 10.1002/cpt.1049

DO - 10.1002/cpt.1049

M3 - Review article

C2 - 29460273

AN - SCOPUS:85044533453

SN - 0009-9236

VL - 103

SP - 795

EP - 801

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

Abstract

Access to Document

Other files and links

Fingerprint

Cite this